Pancreatic Ductal Adenocarcinoma Clinical Trials in Miami, Florida

4 studies are recruiting for pancreatic ductal adenocarcinoma in Miami, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)

    This is a multi-center, non-randomized, single-arm, open-label, phase Ib, dose escalation/dose expansion study of PTM-101 when combined with neoadjuvant chemotherapy for the treatment of treatment-naïve subjects with borderline resectable and locally advanced pancreatic ductal adenocarcinoma (PDAC).

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Miami Sylvester Cancer Center, Miami, Florida
    Locations
    8 in total
    Run by
    PanTher Therapeutics

    See if you can join NCT06673017 on ClinicalTrials.gov

  2. Pancreatic Cancer Early Detection Consortium

    The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and/or individuals carrying…

    Stage
    Not phased
    Ages
    18 to 90
    Site
    University of Miami, Miami, Florida
    Locations
    60 in total
    Run by
    Arbor Research Collaborative for Health

    See if you can join NCT04970056 on ClinicalTrials.gov

  3. Lead-212 PSV359 Therapy for Patients With Solid Tumors

    Phase I/IIa image-guided, alpha-particle therapy study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

    Stage
    Phase 1
    Ages
    18 to 90
    Site
    University of Miami, Miami, Florida
    Locations
    11 in total
    Run by
    Perspective Therapeutics

    See if you can join NCT06710756 on ClinicalTrials.gov

  4. Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma

    The purpose of this study is to understand whether a blood-based test called circulating tumor DNA (ctDNA) can detect whether participants are having a desired tumor shrinkage or an undesired lack of tumor shrinkage, and to study whether these levels of ctDNA can be used to make treatment decisions…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of Miami, Miami, Florida
    Run by
    University of Miami

    See if you can join NCT07096362 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.